Glioblastoma following treatment with fingolimod for relapsing-remitting multiple sclerosis
| Autor: | Nader Pouratian, Nima Golzy, Justin Sharim, Randy S. Tashjian |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
0301 basic medicine
Oncology medicine.medical_specialty Brain tumor Pharmacology Article 03 medical and health sciences Multiple Sclerosis Relapsing-Remitting 0302 clinical medicine Physiology (medical) Internal medicine medicine Humans Brain Neoplasms Fingolimod Hydrochloride business.industry Multiple sclerosis General Medicine Middle Aged medicine.disease Fingolimod nervous system diseases 030104 developmental biology Neurology Relapsing remitting Heart failure Molecular mechanism Female Surgery Neurology (clinical) Glioblastoma business Immunomodulating Agent Immunosuppressive Agents 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | Journal of Clinical Neuroscience. 30:166-168 |
| ISSN: | 0967-5868 |
| DOI: | 10.1016/j.jocn.2016.02.003 |
| Popis: | Glioblastoma is an uncommon and aggressive primary brain tumor with incidence of 3 per 100,000 annually. We report a 50-year-old woman diagnosed with glioblastoma within threeyears of induction of fingolimod therapy for relapsing-remitting multiple sclerosis. Fingolimod, an immunomodulating agent used in the treatment of relapsing-remitting multiple sclerosis, has also been suggested to impart a cardioprotective role in heart failure and arrhythmia via activation of P21-activated kinase-1 (Pak1). In the brain, Pak1 activation has been shown to correlate with decreased survival time amongst patients with glioblastoma. A molecular mechanism underlying a link between fingolimod use and glioblastoma development may involve activation of Pak1. To our knowledge, this is the first report of a potential association between fingolimod use and glioblastoma development. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect